1. 1417PPreliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations. (23rd October 2018) Authors: Pilotto, S; Grizzi, G; Sperduti, I; Simbolo, M; Vicentini, C; Caliò, A; Caccese, M; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Infante, M; Brunelli, M; Scarpa, A; Tortora, G; Bria, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1584PExploring resistance to nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]. (1st October 2019) Authors: Pilotto, S; Vita, E; Sperduti, I; Noia, V P Di; Grizzi, G; D'Argento, E; Simbolo, M; Vicentini, C; Caliò, A; Mafficini, A; Carbognin, L; Corbo, V; Gkountakos, A; Santo, A; Brunelli, M; Martini, M; Scarpa, A; Milella, M; Tortora, G; Bria, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P-186Perihilar and distal extrahepatic cholangiocarcinomas show different genetic profiles but share MYC copy gain and TP53 mutation as independent poor prognostic markers. (2nd July 2019) Authors: Simbolo, M; Mafficini, A; Vicentini, C; Ruzzenente, A; Rusev, B; Brunelli, M; Pedron, S; Bertuzzo, F; Barbi, S; Fassan, M; Corbo, V; Bagante, F; Turri, G; Luchini, C; Lawlor, R; Guglielmi, A; Bassi, C; Scarpa, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗